XGES.L vs. BTEE.L
Compare and contrast key facts about Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGES.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L).
XGES.L and BTEE.L are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. XGES.L is a passively managed fund by DWS that tracks the performance of the MSCI World/Health Care NR USD. It was launched on Jul 12, 2022. BTEE.L is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology TR USD. It was launched on Mar 5, 2018. Both XGES.L and BTEE.L are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
XGES.L vs. BTEE.L - Performance Comparison
Loading graphics...
XGES.L vs. BTEE.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
XGES.L Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | -3.32% | 11.22% | -1.38% | -7.92% | -8.46% |
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 5.00% | 23.36% | 0.03% | 0.55% | 3.40% |
Different Trading Currencies
XGES.L is traded in GBP, while BTEE.L is traded in USD. To make them comparable, the BTEE.L values have been converted to GBP using the latest available exchange rates.
Returns By Period
In the year-to-date period, XGES.L achieves a -3.32% return, which is significantly lower than BTEE.L's 5.00% return.
XGES.L
- 1D
- 2.27%
- 1M
- -2.38%
- YTD
- -3.32%
- 6M
- 4.92%
- 1Y
- 16.23%
- 3Y*
- 0.30%
- 5Y*
- —
- 10Y*
- —
BTEE.L
- 1D
- 2.02%
- 1M
- -0.24%
- YTD
- 5.00%
- 6M
- 19.22%
- 1Y
- 35.84%
- 3Y*
- 10.48%
- 5Y*
- 5.51%
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
XGES.L vs. BTEE.L - Expense Ratio Comparison
Both XGES.L and BTEE.L have an expense ratio of 0.35%.
Return for Risk
XGES.L vs. BTEE.L — Risk / Return Rank
XGES.L
BTEE.L
XGES.L vs. BTEE.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGES.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XGES.L | BTEE.L | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.83 | 1.63 | -0.80 |
Sortino ratioReturn per unit of downside risk | 1.24 | 2.20 | -0.96 |
Omega ratioGain probability vs. loss probability | 1.15 | 1.29 | -0.13 |
Calmar ratioReturn relative to maximum drawdown | 1.25 | 3.52 | -2.27 |
Martin ratioReturn relative to average drawdown | 3.79 | 12.98 | -9.19 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| XGES.L | BTEE.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.83 | 1.63 | -0.80 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.27 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.16 | 0.33 | -0.49 |
Correlation
The correlation between XGES.L and BTEE.L is 0.81, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
XGES.L vs. BTEE.L - Dividend Comparison
XGES.L has not paid dividends to shareholders, while BTEE.L's dividend yield for the trailing twelve months is around 0.36%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
XGES.L Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.36% | 0.37% | 0.46% | 0.39% | 0.44% | 0.25% | 0.17% | 0.14% | 0.07% |
Drawdowns
XGES.L vs. BTEE.L - Drawdown Comparison
The maximum XGES.L drawdown since its inception was -35.79%, which is greater than BTEE.L's maximum drawdown of -30.88%. Use the drawdown chart below to compare losses from any high point for XGES.L and BTEE.L.
Loading graphics...
Drawdown Indicators
| XGES.L | BTEE.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -35.79% | -38.29% | +2.50% |
Max Drawdown (1Y)Largest decline over 1 year | -13.81% | -14.02% | +0.21% |
Max Drawdown (5Y)Largest decline over 5 years | — | -38.29% | — |
Current DrawdownCurrent decline from peak | -14.80% | -2.70% | -12.10% |
Average DrawdownAverage peak-to-trough decline | -18.03% | -13.78% | -4.25% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.55% | 2.81% | +1.74% |
Volatility
XGES.L vs. BTEE.L - Volatility Comparison
The current volatility for Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGES.L) is 6.30%, while iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) has a volatility of 7.30%. This indicates that XGES.L experiences smaller price fluctuations and is considered to be less risky than BTEE.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| XGES.L | BTEE.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.30% | 7.30% | -1.00% |
Volatility (6M)Calculated over the trailing 6-month period | 12.59% | 14.22% | -1.63% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.58% | 21.94% | -2.36% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 18.12% | 20.79% | -2.67% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 18.12% | 22.44% | -4.32% |